
Lytix Biopharma (Q2 Review): FDA Clears Phase III Path for Ruxotemitide

Redeye's analyst just published a Research Update on Lytix Biopharma.

[Click here to read the article](#)

Make sure to add Lytix Biopharma to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your companies.

About Redeye Nordic Growth AB

This is a press release from Redeye Nordic Growth AB, a equity research firm specializing in Nordic growth companies within Tech and Life Science. Redeye Nordic Growth is a part of the Redeye group, which also offers services within corporate finance advisory and fund management. <https://services.redeye.se/>

Attachments

[Lytix Biopharma \(Q2 Review\): FDA Clears Phase III Path for Ruxotemitide](#)